scholarly journals A neutrosophic clinical decision-making system for cardiovascular diseases risk analysis

2020 ◽  
Vol 39 (5) ◽  
pp. 7807-7829
Author(s):  
Shaista Habib ◽  
Wardat us Salam ◽  
M. Arif Butt ◽  
M. Akram ◽  
F. Smarandache

Cardiovascular diseases are the leading cause of death worldwide. Early diagnosis of heart disease can reduce this large number of deaths so that treatment can be carried out. Many decision-making systems have been developed, but they are too complex for medical professionals. To target these objectives, we develop an explainable neutrosophic clinical decision-making system for the timely diagnose of cardiovascular disease risk. We make our system transparent and easy to understand with the help of explainable artificial intelligence techniques so that medical professionals can easily adopt this system. Our system is taking thirty-five symptoms as input parameters, which are, gender, age, genetic disposition, smoking, blood pressure, cholesterol, diabetes, body mass index, depression, unhealthy diet, metabolic disorder, physical inactivity, pre-eclampsia, rheumatoid arthritis, coffee consumption, pregnancy, rubella, drugs, tobacco, alcohol, heart defect, previous surgery/injury, thyroid, sleep apnea, atrial fibrillation, heart history, infection, homocysteine level, pericardial cysts, marfan syndrome, syphilis, inflammation, clots, cancer, and electrolyte imbalance and finds out the risk of coronary artery disease, cardiomyopathy, congenital heart disease, heart attack, heart arrhythmia, peripheral artery disease, aortic disease, pericardial disease, deep vein thrombosis, heart valve disease, and heart failure. There are five main modules of the system, which are neutrosophication, knowledge base, inference engine, de-neutrosophication, and explainability. To demonstrate the complete working of our system, we design an algorithm and calculates its time complexity. We also present a new de-neutrosophication formula, and give comparison of our the results with existing methods.

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Stella Bernardi ◽  
Fleur Bossi ◽  
Barbara Toffoli ◽  
Bruno Fabris

Cardiovascular diseases (CVD) remain the major cause of death and premature disability in Western societies. Assessing the risk of CVD is an important aspect in clinical decision-making. Among the growing number of molecules that are studied for their potential utility as CVD biomarkers, a lot of attention has been focused on osteoprotegerin (OPG) and its ligands, which are receptor activator of nuclear factorκB ligand (RANKL) and TNF-related apoptosis-inducing ligand. Based on the existing literature and on our experience in this field, here we review what the possible roles of OPG and TRAIL in CVD are and their potential utility as CVD biomarkers.


Sign in / Sign up

Export Citation Format

Share Document